Alpha Wave Global LP Takes Position in Certara, Inc. $CERT

Alpha Wave Global LP acquired a new position in Certara, Inc. (NASDAQ:CERT) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 504,724 shares of the company’s stock, valued at approximately $6,168,000. Certara accounts for approximately 0.6% of Alpha Wave Global LP’s portfolio, making the stock its 15th largest holding. Alpha Wave Global LP owned 0.32% of Certara at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Associated Banc Corp grew its stake in Certara by 9.7% during the third quarter. Associated Banc Corp now owns 11,920 shares of the company’s stock valued at $146,000 after acquiring an additional 1,051 shares in the last quarter. Police & Firemen s Retirement System of New Jersey grew its position in shares of Certara by 2.5% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 45,745 shares of the company’s stock valued at $535,000 after purchasing an additional 1,136 shares in the last quarter. Versant Capital Management Inc grew its position in shares of Certara by 66.7% during the third quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after purchasing an additional 1,153 shares in the last quarter. Osaic Holdings Inc. grew its holdings in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares in the last quarter. Finally, Corient Private Wealth LLC grew its holdings in Certara by 11.1% during the 2nd quarter. Corient Private Wealth LLC now owns 12,299 shares of the company’s stock valued at $144,000 after buying an additional 1,232 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

Shares of NASDAQ:CERT opened at $6.65 on Friday. The firm has a market cap of $1.06 billion, a PE ratio of -665.00 and a beta of 1.50. The firm’s 50 day simple moving average is $7.98 and its 200-day simple moving average is $9.62. Certara, Inc. has a one year low of $6.04 and a one year high of $15.38. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.05 and a current ratio of 2.05.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The firm had revenue of $103.65 million during the quarter, compared to analysts’ expectations of $103.23 million. During the same quarter in the previous year, the firm posted $0.15 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. As a group, equities analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CERT shares. TD Cowen reiterated a “buy” rating on shares of Certara in a research report on Thursday, February 26th. Weiss Ratings restated a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Morgan Stanley lowered their price target on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating for the company in a report on Thursday, December 18th. Leerink Partners reissued an “outperform” rating and set a $10.00 price objective on shares of Certara in a research note on Thursday, February 26th. Finally, Wall Street Zen downgraded Certara from a “buy” rating to a “hold” rating in a research report on Sunday, February 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $11.10.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.